November 5, 2026
Perseus Proteomics Inc.
President & CEO: Takuya Yokokawa
e-mail: ir@ppmx.com

Presentation of Observational Study Results for PPMX-T003 Selected for the 68th ASH Annual Meeting

Perseus Proteomics Inc. today announced that an observational study evaluating the pre-trial profiles and long-term outcomes (at 3, 6, 12, and 24 months post-trial) of polycythemia vera (PV) patients enrolled in the Phase I clinical trial of its anti-transferrin receptor 1 (TfR1) antibody, PPMX-T003, has been selected for presentation at the 68th American Society of Hematology (ASH) Annual Meeting, to be held in New Orleans, Louisiana, and virtually from December 12 to 15, 2026. The abstract is now available online.

Presentation Details:

- **Title:** Long-term efficacy and safety of ppmx-T003, an anti-transferrin receptor 1 monoclonal antibody in patients with polycythemia vera and erythrocytosis: Post-phase 1b follow-up study
- **Date & Time:** Sunday, December 13, 2026, 6:00 PM – 8:00 PM (CST)
- **Abstract Number:** 3802
- **Location:** Hall F, Ernest N. Morial Convention Center

About Perseus Proteomics Inc.:

Perseus Proteomics Inc. (Headquarters: Chuo-ku, Tokyo), established in February 2001, is a clinical-stage biotechnology company dedicated to discovering and developing groundbreaking antibody therapeutics, primarily in the oncology field. PPMX-T003 is a first-in-class TfR1-blocking antibody discovered using the company's highly diverse antibody library and its proprietary ICOS method (Patent No. 4870348), which enables efficient target antibody screening. Currently, an investigator-initiated clinical trial of PPMX-T003 is underway for aggressive NK cell leukemia (ANKL). In addition, Perseus Proteomics is advancing the development of PPMX-T002, a radioisotope-labeled antibody, and PPMX-T004, an antibody-drug conjugate (ADC).
For more information, please visit https://www.ppmx.com/